- Home
- JAZZ vs REXR Comparison
JAZZ vs REXR Comparison
Compare JAZZ & REXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | REXR |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 9.7B |
| IPO Year | 2007 | 2013 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | REXR |
|---|---|---|
| Price | $168.86 | $41.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 11 |
| Target Price | ★ $207.19 | $43.00 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 02-24-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 4.19% |
| EPS Growth | N/A | ★ 15.85 |
| EPS | N/A | ★ 1.43 |
| Revenue | ★ $4,157,832,999.00 | $997,931,000.00 |
| Revenue This Year | $6.00 | $8.18 |
| Revenue Next Year | $6.35 | $1.88 |
| P/E Ratio | ★ N/A | $28.79 |
| Revenue Growth | 4.14 | ★ 10.40 |
| 52 Week Low | $95.49 | $29.68 |
| 52 Week High | $182.99 | $44.38 |
Technical Indicators
Market Signals| Indicator | JAZZ | REXR |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 56.41 |
| Support Level | $159.35 | $39.81 |
| Resistance Level | $173.09 | $41.53 |
| Average True Range (ATR) | 5.80 | 0.83 |
| MACD | -0.29 | 0.24 |
| Stochastic Oscillator | 65.44 | 86.04 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About REXR Rexford Industrial Realty Inc.
Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.